Analysts say the stage is set for a gradual pickup in activity in the coming months if volatility subsides.
Convenience store owner Yesway, proteomics company Alamar Biosciences, obesity drug developer Kailera Therapeutics and REIT National Healthcare Properties unveiled the terms for their respective offerings on Monday.
“It speaks to the volume of pre-IPO companies waiting on the sidelines. A number of issuers just need to see some sign of stability and they’ll launch their offerings,” said Matt Kennedy, senior strategist at Renaissance Capital, a provider of IPO-focused research and ETFs.
The VIX Volatility Index, Wall Street’s fear gauge, fell below 20 last week for the first time in over a month.
A reading below 20 can signal increased stability in markets.
IPO REBOUND HOPES INTACTThe IPO market struggled for momentum in February and March as episodes of market volatility linked to AI-disruption fears and the Middle East conflict sidelined issuers.
But “2026 is still on track to be the best year for IPOs since the post-pandemic drought, and it may even get there without the mega listings,” said IPOX Research Associate Lukas Muehlbauer.
“Disciplined pricing and attractive valuations make this a ‘buyer’s market’, giving those deals a stronger chance of trading well after listing.”
From defense to REIT sectors, six companies made their IPO filings public on Friday, bolstering the near-term pipeline.
But some uncertainty persists after weekend talks between the U.S. and Iran failed to deliver a deal to end the war.
Bill Ackman’s Pershing Square also kicked off a roadshow for the U.S. initial public offerings of the billionaire investor’s management company and a new fund.
